Science-Driven Strategy for BioPharma

Science-Driven Strategy for BioPharma

Catenion is a management consulting firm devoted to helping pharmaceutical and biotech companies implement more innovative and effective strategies.

What makes

us unique

  1. We focus on science-driven strategy: we answer key questions through comprehensive multidimensional assessments conducted by our team of life science PhDs.
  1. We have two decades of experience and relationships globally across the biopharmaceutical industry.
  1. We integrate Data Science in our analyses with a team of bioinformaticians, computational biologists and data engineers.

Accelerated Search & Acquisition Process (ASAP)

Catenion's proprietary ASAP is a structured and validated process to screen and select the most fitting companies or assets for potential acquisition or licensing.
Learn More

Science & Technology Mapping

We map landscapes for a given technology or type of therapy to distill strategic insights for our clients.
Learn More

Portfolio Review & Prioritization

We apply established workflows to evaluate projects and entire portfolios to support decision-making and prioritization.
Learn More

Target Identification & Selection

We conduct an established and comprehensive process for the identification and prioritization of the most fitting and attractive biological targets for an asset or technology platform of interest.
Learn More

Commercial Due Diligence

We provide investors with thorough Commercial Due Diligences of lead assets of potential target companies.
Learn More

Therapeutic Expansion & Life Cycle Management

Our Therapeutic Expansion process allows for a systematic search, identification and prioritization of indications that best fit our client’s asset, in line with strategy and needs.
Learn More

Disease Mapping

Our Disease Mapping evaluates the current state, future scenarios and opportunities of an indication or therapeutic area of interest and complements them with internal cross-functional capabilities.
Learn More

R&D Risk Assessment

Catenion's proprietary Risk Assessment tool identifies technical and scientific risks of an R&D program based on over 500 criteria with pre-defined scores and weights.
Learn More

Data Science

At Catenion's Data Science Unit, we develop and employ state-of-the-art computational methods to interpret vast amounts of data and transform them into valuable knowledge. Ultimately, our goal is to synergize data analytics with R&D expertise to design the best drug discovery and development strategies.
Learn More
Hover the tiles to learn more.

Our Clients

& Testimonials

valo health 88945793
“Catenion is an outstanding partner. They deeply understand the needs of a client, work closely with the utmost professionalism and focus on key outcomes, with unwavering focus. Their insights are top notch across the board with true scientific rigor.”
David Berry
Valo Health / Flagship Pioneering
CEO / General Partner
Mkgaa768x432
“When dealing with strategic topics related to R&D, Catenion is my partner of choice. They bring unique perspectives and frameworks, and their deep rooting in science and technology clearly differentiates them from other consulting firms that I know.”
Dr. Stefan Oschmann
Merck KGaA
CEO
Logo Bayer
“One of the toughest decisions I had to take in my role as CEO of Bayer Pharma was to refocus our Discovery activities after the market withdrawal of Lipobay. Using their proprietary tools, benchmarks and a tough, fact–based approach, Catenion guided the Discovery management team through a difficult process of prioritisation of therapeutic areas and projects and provided crucial support for the decision making of the Bayer Corporate Board.”
Dr. Wolfgang Plischke
Bayer Pharma
CEO
Endocyte NovartisCo
“Catenion was able to identify and address the fundamental questions across every aspect of the value chain for each of the programs we assessed. Their insight into the science, regulatory landscape, manufacturing challenges, competitive dynamics, and commercial potential provided an objective understanding of the risks and opportunities.”
Mike Sherman
Endocyte
CEO
download 1
“We have successfully worked with Catenion on various strategic- and portfolio related- topics. They really go deep into the science and are able to translate insights into effective strategies. They are fully at home in the world of US biotech and have an extensive network in Europe and Japan.”
Jon P. Stonehouse
Biocryst Pharmaceuticals Inc.
President and CEO
Note: Affiliations at the time of the collaboration with Catenion.

Insights

In addition to our self-published insights, we also contribute to a variety of different journals on a number of topics. These articles can all be found below.

Catenion Markus Thunecke compressed
“We bridge science, technology and business, working directly with project teams, as well as senior management.”
Dr. Markus Thunecke
Senior Partner
Catenion Matthias Krings
“As trusted partners of top executives in Europe, the US and Japan, we are valued for our objectivity and independent thought.”
Dr. Matthias Krings
Senior Partner
Catenion Mariana Cerdeira 768x994 1
“We develop strategies that empower our clients to drive innovation and bring new treatments from promises to patients.”
Dr. Mariana Cerdeira
Manager
Catenion Arno Heuermann 2
“Translating new technologies into viable business ideas.”
Arno Heuermann
COO, Partner/Managing Director
Catenion Pascal Joly
“At Catenion, I can put my scientific background in cell therapy and regenerative medicine to practical use and help bring innovative therapies to the market.”
Dr. Pascal Joly
Principal
Catenion Ana Rita da Costa
“Catenion provides an exciting workplace where science meets business. We aim to help our clients to reach patients sooner and better.”
Dr. Ana Rita da Costa
Manager
Catenion Christian Elze
“Our uniqueness begins with a deep understanding of what really counts in the pharmaceutical and medical products industries.”
Christian Elze
Senior Partner
Catenion Simin Oz
“At Catenion’s Data Science Unit, we generate data-driven and customized knowledge bases to identify and prioritize indications and drug targets."
Dr. Simin Oz
Manager
Catenion Damir Omerbasic 768x994 1
“Working with clients to identify opportunities and implement solutions to the tough problems in biopharma R&D.”
Dr. Damir Omerbasic
Manager
Catenion Markus Thunecke compressed
“We bridge science, technology and business, working directly with project teams, as well as senior management.”
Dr. Markus Thunecke
Senior Partner
Catenion Matthias Krings
“As trusted partners of top executives in Europe, the US and Japan, we are valued for our objectivity and independent thought.”
Dr. Matthias Krings
Senior Partner
Catenion Mariana Cerdeira 768x994 1
“We develop strategies that empower our clients to drive innovation and bring new treatments from promises to patients.”
Dr. Mariana Cerdeira
Manager
Catenion Arno Heuermann 2
“Translating new technologies into viable business ideas.”
Arno Heuermann
COO, Partner/Managing Director
Catenion Pascal Joly
“At Catenion, I can put my scientific background in cell therapy and regenerative medicine to practical use and help bring innovative therapies to the market.”
Dr. Pascal Joly
Principal
Catenion Ana Rita da Costa
“Catenion provides an exciting workplace where science meets business. We aim to help our clients to reach patients sooner and better.”
Dr. Ana Rita da Costa
Manager
Catenion Christian Elze
“Our uniqueness begins with a deep understanding of what really counts in the pharmaceutical and medical products industries.”
Christian Elze
Senior Partner
Catenion Simin Oz
“At Catenion’s Data Science Unit, we generate data-driven and customized knowledge bases to identify and prioritize indications and drug targets."
Dr. Simin Oz
Manager
Catenion Damir Omerbasic 768x994 1
“Working with clients to identify opportunities and implement solutions to the tough problems in biopharma R&D.”
Dr. Damir Omerbasic
Manager

18

years

Catenion was founded in 2003 by its four senior partners. For over than 18 years, we have been helping our clients develop actionable competitive strategies.

200

companies

companies

Catenion has worked with over 200 companies, from small biotechs to big pharma across the world.

1500

projects

Our consultants have successfully delivered over 1500 projects over the years.

15+

languages

All together, our consultants speak 15+ languages, so wherever we are in the world, we connect with people and respect local cultures.

18

years

Catenion was founded in 2003 by its four senior partners. For over than 18 years, we have been helping our clients develop actionable competitive strategies.

200

companies

companies

Catenion has worked with over 200 companies, from small biotechs to big pharma across the world.

1500

projects

Our consultants have successfully delivered over 1500 projects over the years.

15+

languages

All together, our consultants speak 15+ languages, so wherever we are in the world, we connect with people and respect local cultures.

Contact our Team

Contact our Team

Working

at Catenion

katarina ebert foto.1024x1024
bg tile square

Katarina Ebert

HR Manager

Are you interested in working with us?

We are constantly looking for outstanding candidates to grow our diverse and international team. You should have an excellent academic record in a life science-related subject (PhD preferred), as well as great communication skills, English proficiency, and a team player personality. Having prior strategy consulting experience is helpful but not a pre-requisite. If this sounds like you, please apply directly on our Careers page.

We look forward to receiving your application!